Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BCAB
BioAtla, Inc. Common Stock
stock NASDAQ

At Close
Jul 31, 2026 3:59:48 PM EDT
3.32USD-1.775%(-0.06)13,650
0.00Bid   0.00Ask   0.00Spread
Pre-market
0.00USD-100.000%(-3.38)0
After-hours
Jul 31, 2026 4:00:30 PM EDT
3.29USD-0.904%(-0.03)132
OverviewOption ChainMax PainOptionsPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 11, 2022
08:36AM EST  The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In   Benzinga
Jan 10, 2022
04:07PM EST  BioAtla Announces Clinical Collaboration With Bristol Myers Squibb To Study Mecbotamab Vedotin And Ozuriftamab Vedotin In Combination With Opdivo For Treatment Of Solid Tumors   Benzinga
04:05PM EST  Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo(r) (nivolumab) for Treatment of Solid Tumors   PR Newswire
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Dec 21, 2021
09:02AM EST  BIOATLA APPOINTS EDWARD L. WILLIAMS TO BOARD OF DIRECTORS   PR Newswire
Nov 15, 2021
06:32PM EST  BioAlta Reports Q3 Net Loss Of $229M Compared To A Net Loss Of $11.6M YoY   Benzinga
05:10PM EST  BioAtla Announces Third Quarter 2021 Financial Results And Provides Clinical   PR Newswire
Sep 29, 2021
08:14AM EDT  BioAtla Announces Private Placement Of 2.7M Shares Priced At $28/Share   Benzinga
08:04AM EDT  BioAtla Announces Private Placement of 2.7 Million Shares   PR Newswire
Aug 13, 2021
05:55PM EDT  BioAtla Announces Second Quarter 2021 Financial Results And Provides Clinical   PR Newswire
Jun 28, 2021
10:21AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021   Benzinga
10:03AM EDT  UPDATE: Roth Capital On BioAtla Buy Initiation: Firm Highlights BioAtla Therapies As 'Potentially Having Less Systemic And Off-Target Toxicities And A Broader Therapeutic Index' Than Competitors.   Benzinga
08:53AM EDT  Roth Capital Initiates Coverage On BioAtla with Buy Rating, Announces Price Target of $75   Benzinga
May 12, 2021
06:27PM EDT  BioAtla Announces First Quarter 2021 Financial Results And Provides Business   PR Newswire
Mar 26, 2021
08:57AM EDT  BTIG Maintains Buy on BioAtla, Raises Price Target to $87   Benzinga
Mar 18, 2021
08:16AM EDT  The Daily Biotech Pulse: Translate Bio's Cystic Fibrosis Study Disappoints, Adverum Nominates Directors, Gain Therapeutics To Debut On Nasdaq   Benzinga
Mar 17, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck's Keytruda Gets Label Expansion In Europe, Pfizer To Sell Chinese Biologics Unit, Celcuity Spikes   Benzinga
Mar 12, 2021
07:36AM EST  The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs   Benzinga
Mar 11, 2021
08:19AM EST  The Daily Biotech Pulse: Contrasting COVID-19 Treatment Readouts From Roche, Vir, Delay In Kadmon's FDA Review, Alzheimer's Data From Prothena   Benzinga
Feb 26, 2021
08:17AM EST  The Daily Biotech Pulse: Adcom Test Awaits J&J's COVID-19 Vaccine, Lilly To Supply Additional Antibody Therapy Doses To US, Regulatory Setback For Tricida   Benzinga
Feb 18, 2021
08:14AM EST  The Daily Biotech Pulse: Lily-Rigel Licensing Deal, vTv Starts Early Stage Psoriasis Study, Immunic Data Readout   Benzinga
Feb 16, 2021
06:24AM EST  Pfizer Reported Passive Share Stake of 7% in BioAtla Inc in 13G Filing as of December 31, 2020   Benzinga
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Jan 31, 2021
04:32PM EST  Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More   Benzinga
Jan 15, 2021
07:57AM EST  The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges   Benzinga
Jan 14, 2021
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 11, 2021
10:06AM EST  Benzinga's Top Upgrades, Downgrades For January 11, 2021   Benzinga
06:01AM EST  Credit Suisse Initiates Coverage On BioAtla with Outperform Rating, Announces Price Target of $49   Benzinga
06:00AM EST  Jefferies Initiates Coverage On BioAtla with Buy Rating, Announces Price Target of $51   Benzinga
05:58AM EST  JP Morgan Initiates Coverage On BioAtla with Overweight Rating, Announces Price Target of $45   Benzinga
05:57AM EST  BTIG Initiates Coverage On BioAtla with Buy Rating, Announces Price Target of $47   Benzinga
Jan 9, 2021
01:02PM EST  The Week Ahead In Biotech (Jan 10-16): Expect Stocks To Move As J.P. Morgan Healthcare Conference Kicks Off   Benzinga
Dec 26, 2020
01:53PM EST  Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More   Benzinga
Dec 18, 2020
04:00PM EST  BioAtla Announces Closing of Initial Public Offering and Full Exercise of the   PR Newswire
Dec 16, 2020
12:19PM EST  BioAtla Shares Open For Trade At $30.55; IPO Priced At $18/Share   Benzinga
09:33AM EST  BioAtla Shares Will Open For Quote At 10:10 a.m. EST, Expected To Open For Trade After 10:20 a.m. EST; IPO Priced At $18/Share   Benzinga
Dec 15, 2020
08:07PM EST  BioAtla Prices IPO Of 10.50 Mln Shares At $18.00/shr   RTTNews
08:00PM EST  BioAtla Announces Pricing of Initial Public Offering   PR Newswire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC